检测点注意事项
肌钙蛋白I
介电谱
生物医学工程
免疫分析
全血
注意事项
微流控
电极
检出限
材料科学
纳米技术
心脏标志物
色谱法
肌钙蛋白
电化学
医学
化学
内科学
病理
物理化学
抗体
免疫学
心肌梗塞
作者
Hao Fu,Zhen Qin,Xiao Li,Yueyue Pan,Haitong Xu,Peng Pan,Pengfei Song,Xinyu Liu
出处
期刊:ACS Sensors
[American Chemical Society]
日期:2023-09-14
卷期号:8 (9): 3574-3584
被引量:5
标识
DOI:10.1021/acssensors.3c01221
摘要
Rapid and accurate diagnosis of cardiovascular diseases (CVDs) at the earliest stage is of paramount importance to improve the treatment outcomes and avoid irreversible damage to a patient's cardiovascular system. Microfluidic paper-based devices (μPADs) represent a promising platform for rapid CVD diagnosis at the point of care (POC). This paper presents an electrochemical μPAD (E-μPAD) with an all-in-one origami design for rapid and POC testing of cardiac protein markers in whole blood. Based on the label-free, electrochemical impedance spectroscopy (EIS) immunoassay, the E-μPAD integrates all essential components on a single chip, including three electrochemical cells, a plasma separation membrane, and a buffer absorption pad, enabling easy and streamlined operations for multiplexed detection of three cardiac protein markers [cardiac troponin I (cTnI), brain natriuretic peptide (BNP)-32, and D-Dimer] on a finger-prick whole blood sample within 46 min. Superior analytical performance is achieved through sensitive EIS measurement on carbon electrodes decorated with semiconductor zinc oxide nanowires (ZnO NWs). Using spiked human plasma samples, ultralow limits of detection (LODs) of E-μPAD are achieved at 4.6 pg/mL (190 fM) for cTnI, 1.2 pg/mL (40 fM) for BNP-32, and 146 pg/mL (730 fM) for D-Dimer. Real human blood samples spiked with purified proteins are also tested, and the device's analytical performance was proven to be comparable to commercial ELISA kits. The all-in-one E-μPAD will allow rapid and sensitive testing of cardiac protein markers through easy operations, which holds great potential for on-site screening of acute CVDs in nonlaboratory settings such as emergency rooms, doctor's offices, or patient homes.
科研通智能强力驱动
Strongly Powered by AbleSci AI